Recent studies suggest that anti-PD-1 treatment fails to restore exhausted PD-1+ CD8 T cells to execute anti-tumor surveillance and instead, anti-PD-1 promotes the expansion of this subset of CD8 T cells with enhanced HCC-inducing potential. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.